Celladon – About the Company
Celladon (NasdaqGM: CLDN) is a clinical-stage biopharmaceutical company developing MYDICAR, a gene therapy for the treatment of advanced heart failure. The Company is conducting a 250 patient Phase IIb trial of MYDICAR; enrollment is complete and data are expected in April 2015. The FDA has granted Breakthrough Therapy Designation to the MYDICAR program. The Company is conducting several additional proof-of-concept trials to expand the potential label for MYDICAR therapy to include additional patient groups.